sv se

pHyph


Product development
pHyph is being developed into a local treatment (vaginal tablet) that is expected to cure and prevent bacterial vaginosis.

The active substance in pHyph is GDA 001. The substance is well documented and has always been part of our environment. The substance is well documented and has always been part of our environment. In fact, it is already used as an approved food additive. pHyph is completely free from antibioticspHyph works through two mechanisms of action
• lowers the vaginal pH
• breaks down and prevents the emergence of biofilms


.


 
Bacterial vaginosis In bacterial vaginosis, the normal pH of the vagina is increased and an imbalance occurs in the bacterial flora. The infectious bacteria begin, like the fungi, to thrive under the biofilm.

pHyph breaks down the biofilm and restores the healthy bacterial flora in the vagina by restoring the pH to its natural level (pH 4.5).
  • Prevents bacteria from being established and infecting the vagina.
  • Breaks down the biofilm and restores the pH.
  • Deplaces the infection instead of killing it.

 

 

 

kartaGedea Biotech AB
Medicon Village
Scheelevägen 2
223 81 Lund
Sweden
Annette Säfholm, CEO
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81
nyhetsbrev
Eit